Free tool
FAERS Monitor: Lucemyra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209229 or its brand name (Lucemyra, Lofexidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
163
Serious
46
28% of reports
Hospitalization
24
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness24
- hypotension17
- somnolence15
- dyspnoea14
- diarrhoea13
- dry mouth11
- fatigue11
- insomnia11
- malaise10
- vomiting10
- withdrawal syndrome10
- drug withdrawal syndrome9
- loss of consciousness9
- nausea9
- fall8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 6 |
| 2018 | 19 |
| 2019 | 68 |
| 2020 | 23 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| withdrawal syndromeSignal | 10 | 30.7 | 16.9 | 259 |
| dry mouthSignal | 11 | 17.5 | 9.9 | 156 |
| drug withdrawal syndromeSignal | 9 | 13.2 | 7.0 | 90 |
| hypotensionSignal | 17 | 10.9 | 7.0 | 145 |
| somnolenceSignal | 15 | 9.6 | 5.9 | 108 |
| loss of consciousnessSignal | 9 | 9.1 | 4.8 | 57 |
| dizzinessSignal | 24 | 6.2 | 4.3 | 102 |
| insomniaSignal | 11 | 5.3 | 3.0 | 35 |
| dyspnoeaSignal | 14 | 3.2 | 1.9 | 19 |
| fallSignal | 8 | 3.1 | 1.6 | 10 |
| malaiseSignal | 10 | 2.9 | 1.6 | 11 |
| vomitingSignal | 10 | 2.7 | 1.5 | 10 |
| diarrhoeaSignal | 13 | 2.6 | 1.5 | 12 |
| fatigue | 11 | 1.8 | 1.0 | 3 |
| nausea | 9 | 1.5 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.